Skip to content
TrialScanner

NCT03785249

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Phase 1/Phase 2Active, not recruitingBMYLead

Registry record

Lead sponsor
Mirati Therapeutics Inc.
Conditions
Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
Primary completion
Jun 23, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03785249 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03785249: Phase 1/2 Study of MRTX849... | TrialScanner